Holen Sie sich die Stockscreener-App
2.88
8.57%
-0.27
Handel nachbörslich:
3.00
0.12
+4.17%
Schlusskurs vom Vortag:
$3.15
Offen:
$3.15
24-Stunden-Volumen:
68,405
Relative Volume:
0.70
Marktkapitalisierung:
$1.61B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+6.67%
1M Leistung:
-6.49%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$2.88
$3.155
1-Wochen-Bereich:
$2.64
$3.3312
52-Wochen-Spanne:
$2.51
$6.25
Sl Science Holding Ltd Stock (SLBT) Company Profile
Firmenname
Sl Science Holding Ltd
Sektor
Branche
Telefon
-
Adresse
-
Compare SLBT vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLBT
Sl Science Holding Ltd
|
2.88 | 1.52B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sl Science Holding Ltd Aktie (SLBT) Neueste Nachrichten
SL Science Holding Limited Ordinary Shares (NASDAQ: SLBT) Stock Price, News & Analysis - Kalkine
SL Science Holding (SLBT) Stock May Be Fully Priced Even After A 74% Fall - Yahoo Finance
SL Science Holding Ltd SEC Filing (Aug 13, 2026) - Stock Titan
Upcoming & Recent IPO'sIPOs Calendar - Yahoo Finance
RBGLY Stock Price and Chart — OTC:RBGLY - TradingView
SL Science Leadership Co-Authors Peer-Reviewed Framework for Clinical Development of γδ T Cell Therapy in Glioblastoma - The Manila Times
SL Science Holding Limited Announces Publication of Peer-Reviewed Framework for γδ T Cell Therapy in Glioblastoma - Quiver Quantitative
Brain Cancer Cell Therapy Trials Must Track Cells, Review Says - Stock Titan
AbCellera Stock Soars 30% After Menopause Drug ABCL635 Hits Phase 2 Success In Hot Flash Trial Results - International Business Times Australia
Upcoming and recent IPOs – IPOs calendar - Yahoo Finance UK
Operating expenses (excl. COGS) of SL Science Holding Limited – NASDAQ:SLBT - TradingView
SL Science Holding Ord Shs (SLBT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
SL Science Holding (NASDAQ: SLBT) files to register resale of 1.04M shares - Stock Titan
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Saol Therapeutics Announces the Acceptance of Resubmission of SL1009 (DCA) by the FDA with PDUFA Date of Dec. 30, 2026 - Yahoo Finance
SL Science Holding Ord Shs (SLBT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
SLBT|SL Science Holding Ord Shs|Price:3.200|Chg%:+0.555 - TradingKey
SL Science Holding Ord Shs (SLBT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
SL Science Holding Ord Shs (SLBT) Cash Flow - TradingKey
SL Science Holding Ord Shs (SLBT) Valuation: PE, PB & Fair Value Analysis - TradingKey
SL Science Holding Ord Shs (SLBT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SL Science Holding Ord Shs (SLBT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - tradingkey.com
Kwo Liang Chen Net Worth (2026) - GuruFocus
SLBT|SL Science Holding Ord Shs|Price:3.120|Chg%:-0.050 - TradingKey
SLBT|SL Science Holding Ord Shs|Price:2.620|Chg%:-0.500 - TradingKey
Ching Dong Wang Net Worth (2026) - GuruFocus
Mingche Liu Net Worth (2026) - GuruFocus
The Second Battlefield for Solid Tumor CAR-T: A Global Race in the Intracranial Arena -- Who Is Leading? - Yahoo Finance
Lok Sang Leung Net Worth (2026) - GuruFocus
SL Science presents glioblastoma treatment data at WCP 2026 - Investing.com UK
SL Science presents glioblastoma treatment data at WCP 2026 By Investing.com - Investing.com South Africa
Trevi Therapeutics Shares Surge 13% as Biopharma Investors Cheer Cough Drug Data at London Conference - International Business Times Australia
SL Science Holding Limited Exhibits Breakthrough Gamma Delta T Cell Therapy for Glioblastoma at 2026 World Congress of Basic and Clinical Pharmacology - marketscreener.com
SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology - The Manila Times
SL Science Showcases Preclinical Gamma Delta T Cell Study Demonstrating Glioblastoma Elimination at WCP 2026 - Quiver Quantitative
Preclinical γδ T cells eradicated a brain tumor by day 26 at highest dose - Stock Titan
4DMedical Shares Plunge 15.57% to $3.20 as Volatile ASX Healthcare Stock's Wild Ride Continues This Week - International Business Times Australia
Ericsson, Q32 Bio and other big stocks moving lower in Tuesday’s pre-market session - MSN
Ericsson, Q32 Bio And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Sahm
SL Science seeks US orphan drug designation for γδ T-cell therapy - bioworld.com
Net current asset value per share of SL Science Holding Limited – BOATS:SLBT - TradingView
Number of employees of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Gross margin % of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Price to book ratio of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Net margin % of SL Science Holding Limited – NASDAQ:SLBT - TradingView
SL Science Holding Limited (SLBT-Q) Stock Price and News - The Globe and Mail
Enterprise value to revenue forward of SL Science Holding Limited – BOATS:SLBT - TradingView
Net debt of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Cash flow from investing activities of SL Science Holding Limited – BOATS:SLBT - TradingView
Price to earnings forward of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Finanzdaten der Sl Science Holding Ltd-Aktie (SLBT)
Es liegen keine Finanzdaten für Sl Science Holding Ltd (SLBT) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):